Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm prophylaxis study of recombinant human factor VIII in previously treated children under 12 years with severe hemophilia A
CTR20240584Phase 3Active
- Sponsor
- Zhuangya Medical
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human coagulation factor VIII in hemophilia A, sponsored by Zhuangya Medical. Started Dec 2024; status: active.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20240584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240584.